Abstract: The disclosure provides a handheld power tool, which at least includes a housing assembly, a handle assembly and a switch assembly. The switch assembly includes a button assembly and a push-pull assembly. When the push-pull assembly is configured to complete at least two actions, the button assembly is unlocked, the first action is to slide back and forth along the handle assembly, and the second action is to slide back and forth obliquely along the handle assembly. With the handheld power tool of the disclosure, a trigger switch can be unlocked by a palm, so as to improve a problem of poor comfort during use caused by unlocking the trigger switch by a thumb.

Abstract: The present invention relates to Gamma-amino butyric acid, optionally in combination with a Positive Allosteric Modulator of a GABA-receptor, for use in a method for preventing, or reducing risk of, hypoglycemia in a subject.

Abstract: The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.

Abstract: Diabetes analysis system for analysis and interpretation of data related to glucose level (GL) in blood. The system includes an input module to receive GL related data from measurements of interstitial fluid in subcutaneous tissue, and a hypoglycemia identification module to identify hypoglycemic events by performing a computer-implemented automatic search of the received GL related data. All uninterrupted glucose levels less than a predetermined level in a same time series are considered as one hypoglycemic event. A hypoglycemia classification module analyzes, for each identified event, the glucose data during a predetermined first time period preceding the hypoglycemic event, to determine the glucose level during the first time period.

Abstract: A connector system (47, 48, 49, 50) for a medical application including a male single channel fluid connector (X) designed with an outer collar (M2) arranged concentric with an inner tube (3) and extending beyond a center collar (M1), and a female single channel fluid connector (Y) is designed with an outer collar (F1) arranged concentric with a tube (13), wherein the male single channel fluid connector (X) is interconnectable with the female single channel fluid connector (Y) to thereby form a fluid tight single channel connection for passage of fluid, and to a luer type female single channel fluid connector (YS), and wherein the female single channel fluid connector (Y) is interconnectable with a luer type male single channel fluid connector (XS). Also a system including a plurality of the connector systems is disclosed.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention the glucose and the at least one magnesium salt, are present as anhydrous components in the dialysis acid precursor composition.

Abstract: A male fluid connector, a female fluid connector, and a connection system comprising the connectors. The connection system comprises a male connector and a female connector that both are modified such that they cannot be engaged. The connection system removes the risk of unintentional connection of the two modified connectors not intended to be connected but still allows connection of the two modified connectors to other non-modified connectors.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: The present invention concerns a system for preparing a ready-to-use peritoneal dialysis fluid. The system comprises a) a proportioning device; b) at least one source of water; c) at least one source of first concentrate adapted for connection with a) and b), d) at least one source of second concentrate adapted for connection with a) and b), and optionally, e) at least one source of further concentrate adapted for connection with a) and b), wherein the first concentrate comprises glucose and has a pH of between 1.5 and 4, and wherein the second concentrate comprises a physiologically acceptable buffer and has a pH of between 5.5 and 9.0.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: A connector system (47, 48, 49, 50) for a medical application including a male single channel fluid connector (X) designed with an outer collar (M2) arranged concentric with an inner tube (3) and extending beyond a center collar (M1), and a female single channel fluid connector (Y) is designed with an outer collar (F1) arranged concentric with a tube (13), wherein the male single channel fluid connector (X) is interconnectable with the female single channel fluid connector (Y) to thereby form a fluid tight single channel connection for passage of fluid, and to a luer type female single channel fluid connector (YS), and wherein the female single channel fluid connector (Y) is interconnectable with a luer type male single channel fluid connector (XS). Also a system including a plurality of the connector systems is disclosed.

Abstract: The invention provides a first concentrate comprising lactate and calcium ions, said first concentrate having increased stability against precipitation at temperatures around +4° C., said first concentrate being useful for preparing a ready-to-use dialysis fluid by mixing said first concentrate with water and optionally a second concentrate comprising glucose, wherein that the lactate concentration Lconc (expressed in moles per litre, M) of the concentrate fulfills the conditions: a) Lconc>0.8 M; and b) Lconc<(1.9?0.4×Caready) M; and wherein Caready is the calcium concentration of the ready-to-use dialysis fluid expressed in millimoles per litre (mM).

Abstract: The present invention concerns a system for preparing a ready-to-use peritoneal dialysis fluid. The system comprises a) a proportioning device; b) at least one source of water; c) at least one source of first concentrate adapted for connection with a) and b), d) at least one source of second concentrate adapted for connection with a) and b), and optionally, e) at least one source of further concentrate adapted for connection with a) and b), wherein the first concentrate comprises glucose and has a pH of between 1.5 and 4, and wherein the second concentrate comprises a physiologically acceptable buffer and has a pH of between 5.5 and 9.0.

Abstract: A male fluid connector, a female fluid connector, and a connection system comprising the connectors. The connection system comprises a male connector and a female connector that both are modified such that they cannot be engaged. The connection system removes the risk of unintentional connection of the two modified connectors not intended to be connected but still allows connection of the two modified connectors to other non-modified connectors.

Abstract: Methods and systems for generating a graphical user interface for analysis of red blood cells. The method generates a first view of the graphical user interface by highlighting red blood cells in an image that are classified into at least one group indicated by a user input. The method also generates a second view by extracting individual red blood cells being classified into the at least one group indicated by the user input from the image of red blood cells and displaying them group-wise.

Abstract: The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.

Abstract: A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 ?M, and rubidium in a concentration of 1.4-4.2 ?M. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper.